NCT07200544 Meloxicam in Mohs Micrographic Surgery
| NCT ID | NCT07200544 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | University of Oklahoma |
| Condition | Postoperative Pain, Acute |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2025-10-15 |
| Primary Completion | 2026-06-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 300 participants in total. It began in 2025-10-15 with a primary completion date of 2026-06-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to explore alternative methods of postoperative pain control in Mohs micrographic surgery. The main aims are: * To provide more information to the Mohs surgery community regarding postoperative pain control. * Reducing pain improves the overall comfort and well-being of patients, leading to a better post-operative experience. * To provide patients with an alternative and potentially superior NSAID for pain control (compared to standard-of-care ibuprofen). Researchers will compare 1) a single of dose Meloxicam 7.5 mg, followed by acetaminophen 500 mg; 2) a single dose of Meloxicam 15 mg, followed by acetaminophen 500 mg; 3) a single dose of acetaminophen 500 mg, followed by alternating ibuprofen 200 mg and acetaminophen 500 mg to see which better moderate pain control and patient satisfaction. Participants will be asked to complete pain and patient satisfaction surveys.
Eligibility Criteria
Inclusion Criteria: * All adult patients who consents to the study and are undergoing Mohs micrographic surgery at the University of Oklahoma. Exclusion Criteria: * Women who are pregnant, suspected to be pregnant, or planning to become pregnant during the study period will be excluded from participation. * Chronic liver disease (chronic hepatitis, acute hepatitis, cirrhosis, NASH, NAFLD, alcoholic liver disease, hemochromatosis, Wilson's disease) * Chronic kidney disease stage III or greater, * Aspirin-sensitive asthma * History of chronic NSAID use * Patients vulnerable to drug interactions * GI bleeds * Peptic ulcers * Non-English speakers
Contact & Investigator
Lindsey Collins, MD
PRINCIPAL INVESTIGATOR
University of Oklahoma, Department of Dermatology
Frequently Asked Questions
Who can join the NCT07200544 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 110 Years, studying Postoperative Pain, Acute. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07200544 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07200544 currently recruiting?
Yes, NCT07200544 is actively recruiting participants. Contact the research team at chase-pitchford@ouhsc.edu for enrollment information.
Where is the NCT07200544 trial being conducted?
This trial is being conducted at Oklahoma City, United States.
Who is sponsoring the NCT07200544 clinical trial?
NCT07200544 is sponsored by University of Oklahoma. The principal investigator is Lindsey Collins, MD at University of Oklahoma, Department of Dermatology. The trial plans to enroll 300 participants.